Tebentafusp after treatment for high-risk eye melanoma
Treatments studied
Part of Cancer, Eyes & vision clinical trials.
This trial tests a new drug called tebentafusp given after standard treatment (surgery or radiation) for high-risk uveal melanoma that hasn't spread. The goal is to see if it helps prevent the cancer from coming back.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have been treated for uveal melanoma (not iris melanoma) and it has not spread beyond the eye.
- Your tumor is considered high-risk, either because it was stage 3 or because genetic tests showed certain markers.
- You have a specific genetic marker called HLA-A*02:01 (a blood test can tell this).
- It has been less than 11 weeks since your primary treatment (surgery or radiation).
- You are in good overall health (able to do daily activities, no serious heart or immune conditions).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial provides access to tebentafusp, a treatment for advanced melanoma of the eye that cannot be removed by surgery. It may help control the disease.
This trial tests a new drug called tebentafusp for people with uveal melanoma that has spread to other parts of the body and who have not yet received any treatment for the metastatic disease. It requires a specific genetic marker (HLA-A*0201) and focuses on whether the drug can shrink or slow the growth of tumors.
This trial tests if adding another drug called IL-2 to tebentafusp can help stop cancer from growing in people with advanced melanoma that started in the eye (uveal melanoma). It is for those whose cancer got worse while on tebentafusp alone.
This trial tests a new drug (RBP-01) given before standard treatment for uveal melanoma, a type of eye cancer. The goal is to see if the drug can shrink the tumor or improve outcomes for people who need eye removal or high-risk radiation therapy.
This trial is testing a combination of two oral medications (darovasertib and crizotinib) after standard local treatment for high-risk uveal melanoma that has not spread. The goal is to see if this treatment can reduce the risk of the cancer coming back.
This study follows people with high-risk uveal (eye) melanoma after their initial treatment to better understand relapse risk. It may help your care team track you more closely using scheduled visits and blood tests.
Hear when a new Uveal Melanoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.